Specify a stock or a cryptocurrency in the search bar to get a summary
Aprea Therapeutics Inc
APREAprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania. Address: 3805 Old Easton Road, Doylestown, PA, United States, 18902
Analytics
WallStreet Target Price
15.67 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures APRE
Dividend Analytics APRE
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History APRE
Stock Valuation APRE
Financials APRE
Results | 2019 | Dynamics |